RT Journal Article
SR Electronic
T1 Biomarkers to predict FEV1 decline in smokers and early-onset COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2712
DO 10.1183/13993003.congress-2020.2712
VO 56
IS suppl 64
A1 Carolina Gotera
A1 Antonio Pereira Vega
A1 Tamara García Barrera
A1 José María Marín Trigo
A1 Ciro Casanova Macario
A1 Borja García-Cosío Piqueras
A1 Isabel Mir Viladrich
A1 Ingrid Solanes García
A1 José Luis Gómez Ariza
A1 José Luis López Campos
A1 Luis Seijo Maceiras
A1 Nuria Feu Collado
A1 Carlos Cabrera López
A1 Carlos Amado Diago
A1 Amparo Romero Plaza
A1 Juan Pablo De Torres Tajes
A1 Luis Alejandero Padrón Fraysse
A1 Eduardo Márquez Martín
A1 Margarita Marín Royo
A1 Eva Balcells Vilarnau
A1 Antonia Llunell Casanovas
A1 Cristina Martínez González
A1 Juan Bautista Galdiz Iturri
A1 Celia Lacárcel Bautista
A1 Sandra García Garrido
A1 Germán Peces-Barba
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/2712.abstract
AB Introduction: FEV1 is the standard clinical marker of COPD, but biomarkers (BM) capable of predicting the onset or progression of disease are needed.Objective: identify BM of clinical utility in the diagnosis and prediction possibilities in FEV1 decliners.Materials and Methods: We conducted a metabolomic analysis in individuals from the CHAIN cohort. For this purpose, blood and post-bronchodilator FEV1 were recorded. Two groups of comparisons were carried out in mild COPD (mCOPD) (n=31) and smokers without COPD as control (C) (n=31). The test by GC-MS and FIA was performed. The results were processed to construct PLS-DA and compare the metabolomic profiles obtained.Results: PLS-DA notably differentiates mCOPD from C (Fig. 1A, 1B, and 1C). Oleic acid, palmitic acid, urea, inositol, and glucose had the best AUC values in the group with accelerated FEV1 decline (Table2). Additionally, we observed a decrease in fatty acids and amino acids (phenylalanine, leucine, pyroglutamate, proline, threonine, and valine) in contrast to the increase in phosphocholine (Fig. 2A and 2B).Conclusions: Smokers can experience accelerated declines in lung function similar to those seen in mCOPD. Metabolomic analysis identified six metabolites associated with rapid functional decline.Acknowledgment: Scholarship not conditioned by Menarini laboratories.Scholarship not conditioned by AstraZeneca laboratories.Scholarship project IIS-AES PI16/01FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2712.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).